Pasithea Therapeutics (KTTA) Enterprise Value (2020 - 2026)
Pasithea Therapeutics recorded quarterly Enterprise Value of -$50.5 million in Q1 2026, up 8.61% quarter-over-quarter from -$55.3 million in Q4 2025, and down 845.49% year-over-year from $6.8 million in Q1 2025.
Pasithea Therapeutics' Enterprise Value history runs 7 years deep, the most recent figure standing at -$50.5 million for Q1 2026.
- In Q1 2026, Enterprise Value fell 845.49% year-over-year to -$50.5 million; the TTM figure through Mar 2026 stood at -$50.5 million (down 845.49% YoY), while the FY2025 annual figure was -$55.3 million, down 805.9% from the prior year.
- Enterprise Value came in at -$50.5 million for Q1 2026 at Pasithea Therapeutics, up from -$55.3 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$16634.0 in Q1 2023 to a low of -$55.3 million in Q4 2025.
- A 5-year average of -$23.0 million and a median of -$13.4 million in 2023 frame the typical range for Enterprise Value.
- Across the five-year window, Enterprise Value surged 99.97% in 2023 and slumped 72041.4% in 2024, its largest moves.
- Pasithea Therapeutics' Enterprise Value stood at -$33.1 million in 2022, then soared by 59.5% to -$13.4 million in 2023, then jumped by 54.48% to -$6.1 million in 2024, then slumped by 805.9% to -$55.3 million in 2025, then advanced by 8.61% to -$50.5 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$50.5 million, -$55.3 million, and -$4.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.32 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | -32.30 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -286.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | -61.46 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -2.77 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | -7.25 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -3.01 Bn |
| 10 | Pasithea Therapeutics | 17.41 Mn | 17.41 Mn | - | -50.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -50.50 Mn |
| Dec 31, 2025 | -55.30 Mn |
| Sep 30, 2025 | -4.22 Mn |
| Jun 30, 2025 | -7.20 Mn |
| Mar 31, 2025 | -4.10 Mn |
| Dec 31, 2024 | -6.92 Mn |
| Sep 30, 2024 | -9.36 Mn |
| Jun 30, 2024 | -7.10 Mn |
| Mar 31, 2024 | -12.01 Mn |
| Dec 31, 2023 | -16.33 Mn |
| Sep 30, 2023 | -10.40 Mn |
| Jun 30, 2023 | -26.77 Mn |
| Mar 31, 2023 | -29.91 Mn |
| Dec 31, 2022 | -33.09 Mn |
| Sep 30, 2022 | -42.40 Mn |
| Jun 30, 2022 | -47.94 Mn |
| Mar 31, 2022 | -50.32 Mn |
| Dec 31, 2021 | -52.97 Mn |
| Sep 30, 2021 | -20.57 Mn |
| Dec 31, 2020 | -243,650.00 |